Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment

dc.contributor
Institut Català de la Salut
dc.contributor
[Espín R, Sigüenza-Andrade J, Farran-Matas S, Mateo F, Figueras A] ProCURE, Catalan Institute of Oncology, L’Hospitalet del Llobregat, Barcelona, Spain. Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat, Barcelona, Spain. [Medina-Jover F] ProCURE, Catalan Institute of Oncology, L’Hospitalet del Llobregat, Barcelona, Spain. Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat, Barcelona, Spain. Department of Physiological Sciences, University of Barcelona, Barcelona, Spain. [Serra V] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Espin Garcia, Roderic
dc.contributor.author
Medina-Jover, Ferran
dc.contributor.author
Sigüenza-Andrade, Javier
dc.contributor.author
Farran Matas, Sònia
dc.contributor.author
Mateo, Francesca
dc.contributor.author
Figueras, Agnès
dc.contributor.author
Serra, Violeta
dc.date.accessioned
2025-10-25T05:37:10Z
dc.date.available
2025-10-25T05:37:10Z
dc.date.issued
2025-04-22T07:02:57Z
dc.date.issued
2025-04-22T07:02:57Z
dc.date.issued
2025-03
dc.identifier
Espín R, Medina-Jover F, Sigüenza-Andrade J, Farran-Matas S, Mateo F, Figueras A, et al. Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment. NAR Cancer. 2025 Mar;7(1):zcaf007.
dc.identifier
2632-8674
dc.identifier
http://hdl.handle.net/11351/12969
dc.identifier
10.1093/narcan/zcaf007
dc.identifier
40061566
dc.identifier
001438817900001
dc.identifier.uri
http://hdl.handle.net/11351/12969
dc.description.abstract
Transcriptional regulation; Cancer treatment
dc.description.abstract
Regulación transcripcional; Tratamiento del cáncer
dc.description.abstract
Regulació transcripcional; Tractament del càncer
dc.description.abstract
Alternative end-joining (alt-EJ) is an error-prone DNA repair pathway that cancer cells deficient in homologous recombination rely on, making them vulnerable to synthetic lethality via inhibition of poly(ADP-ribose) polymerase (PARP). Targeting alt-EJ effector DNA polymerase theta (POLθ), which synergizes with PARP inhibitors and can overcome resistance, is of significant preclinical and clinical interest. However, the transcriptional regulation of alt-EJ and its interactions with processes driving cancer progression remain poorly understood. Here, we show that alt-EJ is suppressed by hypoxia while positively associated with MYC (myelocytomatosis oncogene) transcriptional activity. Hypoxia reduces PARP1 and POLQ expression, decreases MYC binding at their promoters, and lowers PARylation and alt-EJ-mediated DNA repair in cancer cells. Tumors with HIF1A mutations overexpress the alt-EJ gene signature. Inhibition of hypoxia-inducible factor 1α or HIF1A expression depletion, combined with PARP or POLθ inhibition, synergistically reduces the colony-forming capacity of cancer cells. Deep learning reveals the anticorrelation between alt-EJ and hypoxia across regions in tumor images, and the predictions for these and MYC activity achieve area under the curve values between 0.70 and 0.86. These findings further highlight the critical role of hypoxia in modulating DNA repair and present a strategy for predicting and improving outcomes centered on targeting alt-EJ.
dc.description.abstract
This study was funded by the “GINKGO Apac del Berguedà” patient association; the Instituto de Salud Carlos III [co-funded by the European Regional Development Fund (ERDF), “A way to build Europe”] grants PI21/0136 and PI24/01327 to M.A.P., and PI19/00342 and PI23/00513 to A.A.; the Asociación Española Contra el Cáncer (AECC) grant LABAE21170 to A.A.; the Department of Defense PC210340 PCRP-IDA grant to A.A.; the Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación [co-funded by the European Regional Development Fund (ERDF), “A way to build Europe”] grants PID2020-117815RB-I00 and PID2023-150836OB-100 to F.V., and CNS2023-145615 to A.A.; and the Generalitat de Catalunya, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) grants SGR 2017-449 and 2021-00184 to F.V. and M.A.P., and 2021-00895 to A.A. R.E. and M.A.P.-C. were supported by contracts from the Departament de Salut, Generalitat de Catalunya, PERIS-PFI SLT017-20-000076 and PERIS-Suport SLT017/20/000072, respectively, and A.S. was supported by Generalitat de Catalunya AGAUR fellowship 2022-FI-B01068. We also acknowledge the support of the Centres de Recerca de Catalunya (CERCA) Program to IDIBELL and IDIBGI. The open-access publication of this article was funded by the Instituto de Salud Carlos III grants PI24/01327 to M.A.P., PI23/00513 to A.A., and PID2023-150836OB-100 to F.V.
dc.format
application/pdf
dc.language
eng
dc.publisher
Oxford University Press
dc.relation
NAR Cancer;7(1)
dc.relation
https://doi.org/10.1093/narcan/zcaf007
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Scientia
dc.subject
Càncer - Tractament
dc.subject
Càncer - Aspectes genètics
dc.subject
ADN - Reparació
dc.subject
Inhibidors enzimàtics - Ús terapèutic
dc.subject
PHENOMENA AND PROCESSES::Chemical Phenomena::Biochemical Phenomena::DNA Repair::DNA End-Joining Repair
dc.subject
DISEASES::Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Poly(ADP-ribose) Polymerase Inhibitors
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
FENÓMENOS Y PROCESOS::fenómenos químicos::fenómenos bioquímicos::reparación del ADN::reparación del ADN por unión de extremos
dc.subject
ENFERMEDADES::neoplasias
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de poli(ADP-ribosa) polimerasas
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)